Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually. Details of the presentation are as follows: Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC Abstract Number: 765 Presenter: Reid Bissonnette, Ph.D.

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Xenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has entered into a Materials Transfer Agreement with Tokyo Medical University to advance the development of its systemic DNase program. Under the terms of the agreement, Professor Takuro Nakamura of the Department of Experimental Pathology, Institute of Medical Science at Tokyo Medical University will lead the research program evaluating the effects of human recombinant DNase I (rhDNase I) when given in combination with chemotherapy in a proprietary immunocompetent preclinical mouse model of Ewing sarcoma.

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jim Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, presented at the H.C. Wainwright 26 th Annual Global Investment Conference.

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Ongoing preclinical studies with data expected before year end Focus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indications Ended the quarter with $7.3 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / August 14, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2024. "We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before year end.

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.83 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.69 per share a year ago.

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the quarter with $7.8 million of cash to fund operations    FRAMINGHAM, MA / ACCESSWIRE / May 10, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2024 and provided a business update. "We have initiated several preclinical studies on the influence of DNase in combination with standard treatment paradigms such as chemotherapy or immune checkpoint blockade and expect to present results in the second half of this year.

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.60 per share a year ago.

Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates

Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the year ended December 31, 2023. Recent Highlights Entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of the DNase program.

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of its systemic DNase program. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps ("NETs"), which are weblike structures composed of extracellular chromatin coated with histones and other proteins.

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Continuing partnering discussions to advance development of systemic DNase and DNase-Armored CAR T programs Ended the quarter with $9.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / November 10, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter ended September 30, 2023. "Over the past quarter we continued to see encouraging preclinical data across our DNase platform modalities that is advancing our programs toward first-in-human clinical studies.

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences, will participate at the Virtual Investor Ask the CEO Conference on October 24, 2023 at 1:00 PM ET. The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management.

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors FRAMINGHAM, MA / ACCESSWIRE / August 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2023. "Since the beginning of 2023, we have taken important, fundamental steps to further advance our DNase-based oncology platform.

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Xenetic Biosciences (XBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Live moderated video webcast on Wednesday, July 12th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer and Curtis A. Lockshin, PhD, Chief Scientific Officer of Xenetic Biosciences will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 10:00 AM ET.

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

FRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m.

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors - Ended the quarter with $12.0 million of cash to fund operations and drive pipeline forward FRAMINGHAM, MA / ACCESSWIRE / May 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2023 and provided a business update. "We made solid progress with our DNase platform by the establishment of a research and development collaboration with The Scripps Research Institute.

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise FRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P. Bissonnette, Ph.D.

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.

Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning FRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform.

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development - Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma FRAMINGHAM, MA / ACCESSWIRE / April 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has entered into a Research Funding and Option Agreement (the "Agreement") with The Scripps Research Institute ("TSRI") to advance the development of the Company's systemic DNase program as well as its DNase-armored CAR T program. The systemic DNase program is expected to be evaluated in combination with existing therapies for the potential treatment of pancreatic carcinoma and other solid tumor indications.

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Phase 1 clinical development - Closed the year with $13.1 million of cash expected to fund operations and drive pipeline development FRAMINGHAM, MA / ACCESSWIRE / March 23, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the full year 2022 and provided a business update. "2022 represented a transformational year for the Company.

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET - FRENCHTOWN, NJ / ACCESSWIRE / March 16, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor NETs in Cancer Spotlight Event featuring Xenetic Biosciences on Wednesday, March 29, 2023, at 11:00 AM ET. Access the event here.

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / March 16, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that it will participate in the Virtual Investor NETs in Cancer Spotlight Event on Wednesday, March 29, 2023 at 11:00 AM ET. For the roundtable discussion, Jeffrey F.

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

FRAMINGHAM, MA / ACCESSWIRE / January 17, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,001,543 titled, "Method to Improve Safety and Efficacy of Anti-Cancer Therapy.

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

Live video webcast on Tuesday, January 17th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 10:00 AM ET. A live video webcast of the presentation will be available on the Events page in the Investors section of the Company's website (www.XeneticBio.com).

News for Xenetic Biosciences Stock (XBIO)